REG - Sareum Holdings PLC - Results of AGM

Sareum HoldingsAnnouncement

19/12/2024 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241219:nRSS8213Qa&default-theme=true

RNS Number : 8213Q  Sareum Holdings PLC  19 December 2024

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 19 December 2024 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, held its Annual General Meeting
("AGM") today and all resolutions were duly passed. Voting was conducted by a
show of hands and inclusive of votes received by the Company by way of proxy.

 

Details of the proxy voting results are shown in the table below.

 

 Ordinary Resolutions                                                    Votes For   %      Votes Against  %     Votes Total  % of ISC Voted  Votes Withheld
 1. Receive the financial statements for the year                        11,916,088  99.38  74,805         0.62  11,990,893   9.61%           163,189
 2. Receive and approve the Directors' Renumeration Report for the year  11,800,364  98.55  174,011        1.45  11,974,375   9.60%           179,707
 3. Re-elect Mr Clive Birch as Director of the Company                   10,443,572  92.12  893,439        7.88  11,337,011   9.09%           817,071
 4. Re-elect Dr Michael Owen as Director of the Company                  10,443,672  92.12  893,339        7.88  11,337,011   9.09%           817,071
 5. Re-appoint Shipleys LLP as auditor                                   11,775,627  98.70  154,926        1.30  11,930,553   9.56%           223,529
 6. Authorise the audit committee to determine auditor renumeration      11,856,252  99.29  84,641         0.71  11,940,893   9.57%           213,189
 7. Directors' authority to allot new shares                             11,538,681  96.23  451,872        3.77  11,990,553   9.61%           163,529
 Special Resolution
 8. Directors' authority to disapply pre-emption rights                  11,522,085  96.30  442,974        3.70  11,965,059   9.59%           189,023
 9. Authority to hold general meetings                                   11,893,866  99.29  84,805         0.71  11,978,671   9.60%           175,411

 

The full text of each of the resolutions is set out in the Notice of AGM,
available in the Investors section of the Company's website
(www.sareum.com/investors (http://www.sareum.com/investors/document-centre/) )

 

For further information, please contact:

 Sareum Holdings plc

 Stephen Parker, Executive Chaiman                 01223 497700

                                                   ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                       020 7409 3494

 Oberon Capital (Joint Broker)

 Mike Seabrook / Nick Lovering                     020 3179 5300

 Hybridan LLP (Joint Broker)

 Claire Noyce                                      020 3764 2341

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Davide Salvi / Kumail Walijee   020 3709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, including
psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFLFIRFRLALIS